{
    "cit1": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Heart failure has become a global health problem with projections of increasing prevalence and rising economic burden in the next decade (Cook, Cole, Asaria, Jabbour, & Francis, 2014; Mozaffarian et al., 2015).",
        "REFERENCE": "(Cook, Cole, Asaria, Jabbour, & Francis, 2014;",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit2": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Heart failure has become a global health problem with projections of increasing prevalence and rising economic burden in the next decade (Cook, Cole, Asaria, Jabbour, & Francis, 2014; Mozaffarian et al., 2015).",
        "REFERENCE": "Mozaffarian et al., 2015)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit3": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Together, these processes may lead to adverse cardiac remodelling, which if left untreated can eventually progress to heart failure (Burchfield, Xie, & Hill, 2013).",
        "REFERENCE": "(Burchfield, Xie, & Hill, 2013)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit4": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "At the initial stage of remodelling, hypertrophic growth is regarded as an adaptive response to reduce stress on the ventricular wall (Hill & Olson, 2008).",
        "REFERENCE": "(Hill & Olson, 2008)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit5": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "However, in the long term, hypertrophy is likely to produce detrimental effects since a number of clinical data have shown strong associations between cardiac hypertrophy and the incidence of heart failure (Yang, Negishi, Otahal, & Marwick, 2015).",
        "REFERENCE": "(Yang, Negishi, Otahal, & Marwick, 2015)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit6": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Cardiac pressure overload through the increase of mechanical wall stress and activation of neurohormonal factors induces a number of molecular signalling pathways that are involved in promoting cardiomyocyte growth (Heineke & Molkentin, 2006).",
        "REFERENCE": "(Heineke & Molkentin, 2006)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit7": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "On the other hand, pressure overload also induces significant cardiomyocyte death (Hein et al., 2003).",
        "REFERENCE": "(Hein et al., 2003)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit8": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Apoptosis appears to play a major role in mediating cell death since prolonged pressure overload triggers expression of proapoptotic proteins and reduces the level of anti-apoptotic molecules (Kuster et al., 2005).",
        "REFERENCE": "(Kuster et al., 2005)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit9": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Importantly, it has been associated with a number of key pathophysiological processes in the heart, such as regulation of cardiomyocyte apoptosis (Matsui et al., 2008; Yamamoto et al., 2003), cardiac hypertrophy (Zi et al., 2014), autophagy (Maejima et al., 2013), and cardiomyocyte proliferation (Heallen et al., 2013).",
        "REFERENCE": "(Matsui et al., 2008;",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit10": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Importantly, it has been associated with a number of key pathophysiological processes in the heart, such as regulation of cardiomyocyte apoptosis (Matsui et al., 2008; Yamamoto et al., 2003), cardiac hypertrophy (Zi et al., 2014), autophagy (Maejima et al., 2013), and cardiomyocyte proliferation (Heallen et al., 2013).",
        "REFERENCE": "Yamamoto et al., 2003)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit11": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Importantly, it has been associated with a number of key pathophysiological processes in the heart, such as regulation of cardiomyocyte apoptosis (Matsui et al., 2008; Yamamoto et al., 2003), cardiac hypertrophy (Zi et al., 2014), autophagy (Maejima et al., 2013), and cardiomyocyte proliferation (Heallen et al., 2013).",
        "REFERENCE": "(Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit12": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Importantly, it has been associated with a number of key pathophysiological processes in the heart, such as regulation of cardiomyocyte apoptosis (Matsui et al., 2008; Yamamoto et al., 2003), cardiac hypertrophy (Zi et al., 2014), autophagy (Maejima et al., 2013), and cardiomyocyte proliferation (Heallen et al., 2013).",
        "REFERENCE": "(Maejima et al., 2013)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit13": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Importantly, it has been associated with a number of key pathophysiological processes in the heart, such as regulation of cardiomyocyte apoptosis (Matsui et al., 2008; Yamamoto et al., 2003), cardiac hypertrophy (Zi et al., 2014), autophagy (Maejima et al., 2013), and cardiomyocyte proliferation (Heallen et al., 2013).",
        "REFERENCE": "(Heallen et al., 2013)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit14": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "In the heart, the pathway is thought to be activated by a variety of upstream stress signals including ROS, mechanical stress, and GPCR signalling (Zhou, Li, Zhao, & Guan, 2015).",
        "REFERENCE": "(Zhou, Li, Zhao, & Guan, 2015)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit15": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Notably, the expression and activation of core components of the Hippo pathway such as YAP, Lats, and Salv were significantly elevated in patients with heart failure (Leach et al., 2017) and we have previously shown expression of Mst2 was increased in a mouse model of pressure overload hypertrophy (Zi et al., 2014).",
        "REFERENCE": "(Leach et al., 2017)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit16": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Notably, the expression and activation of core components of the Hippo pathway such as YAP, Lats, and Salv were significantly elevated in patients with heart failure (Leach et al., 2017) and we have previously shown expression of Mst2 was increased in a mouse model of pressure overload hypertrophy (Zi et al., 2014).",
        "REFERENCE": "(Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit17": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "The two main core kinases of the Hippo pathway, the Mst1 and Mst2, have been implicated in the regulation of cell apoptosis (Galan & Avruch, 2016).",
        "REFERENCE": "(Galan & Avruch, 2016)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit18": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Overactivation of Mst1 in cardiomyocytes led to severe cardiomyopathy due to induction of apoptosis (Yamamoto et al., 2003).",
        "REFERENCE": "(Yamamoto et al., 2003)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit19": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "Interestingly, the second isoform of this enzyme (i.e., Mst2) has been implicated in cardiac hypertrophy (Zi et al., 2014).",
        "REFERENCE": "(Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit20": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "As pharmacological therapy that directly targets intra-cardiac molecules to control adverse remodelling is currently limited (Xie, Burchfield, & Hill, 2013), targeting Mst1/2 could become a promising approach to address this problem.",
        "REFERENCE": "(Xie, Burchfield, & Hill, 2013)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit21": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "A recent study (Fan et al., 2016) described a novel benzenesulfonamide, XMU-MP-1, that selectively inhibited Mst1 and Mst2 with IC 50 values of 71 and 38 nM, respectively.",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit22": {
        "SECTION": "| INTRODUCTION",
        "CITATION": "In vivo, XMU-MP-1 treatment induced regeneration of the liver and intestine after injury in mice, through the modulation of the Hippo pathway (Fan et al., 2016).",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Introduction"
        ]
    },
    "cit23": {
        "SECTION": "| METHODS",
        "CITATION": "Neonatal rat cardiomyocytes (NRCM) were isolated from 2-to 3-dayold Sprague Dawley rat neonates using a protocol described previously (Mohamed et al., 2016).",
        "REFERENCE": "(Mohamed et al., 2016)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit24": {
        "SECTION": "| METHODS",
        "CITATION": "YAP activity was determined using a luciferase reporter assay as described by Tian, Yu, Tomchick, Pan, and Luo (2010).",
        "REFERENCE": "Tian, Yu, Tomchick, Pan, and Luo (2010)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit25": {
        "SECTION": "| METHODS",
        "CITATION": "The Gal4‐TEAD4 construct was a gift from Dr Kunliang Guan (Addgene plasmid #24640; http://n2t.net/addgene:24640; RRID:Addgene_24640), whereas the pUAS‐luc2 was a gift from Dr Liqun Luo (Addgene plasmid # 24343; http://n2t.net/addgene:24343; RRID:Addgene_24343; Potter, Tasic, Russler, Liang, & Luo, 2010).",
        "REFERENCE": "Potter, Tasic, Russler, Liang, & Luo, 2010)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit26": {
        "SECTION": "| METHODS",
        "CITATION": "The GFP‐YAP construct (pEGFP‐C3‐hYAP1) was a gift from Dr Marius Sudol (Addgene plasmid # 17843; http://n2t.net/addgene:17843; RRID:Addgene_17843; Basu, Totty, Irwin, Sudol, & Downward, 2003).",
        "REFERENCE": "Basu, Totty, Irwin, Sudol, & Downward, 2003)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit27": {
        "SECTION": "| METHODS",
        "CITATION": "Animal experiments are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) and with the recommendations made by the British Journal of Pharmacology.",
        "REFERENCE": "(Kilkenny et al., 2010;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit28": {
        "SECTION": "| METHODS",
        "CITATION": "Animal experiments are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) and with the recommendations made by the British Journal of Pharmacology.",
        "REFERENCE": "McGrath & Lilley, 2015)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit29": {
        "SECTION": "| METHODS",
        "CITATION": "Details of the TAC procedure are described in our previous publications (Mohamed et al., 2016; Zi et al., 2014).",
        "REFERENCE": "(Mohamed et al., 2016;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit30": {
        "SECTION": "| METHODS",
        "CITATION": "Details of the TAC procedure are described in our previous publications (Mohamed et al., 2016; Zi et al., 2014).",
        "REFERENCE": "Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit31": {
        "SECTION": "| METHODS",
        "CITATION": "These animals were allocated to vehicle-or XMU-MP-1-treated groups using a randomised block design as described by Festing, Overend, Das, Borja, and Berdoy (2004).",
        "REFERENCE": "Festing, Overend, Das, Borja, and Berdoy (2004)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit32": {
        "SECTION": "| METHODS",
        "CITATION": "The dosing regimen was based on the pharmacokinetics data of XMU-MP-1 in a rodent model (Fan et al., 2016) and functional assays showing the effects of XMU-MP-1 injection (1 mg•kg -1) in reducing MOB1 phosphorylation in mice (Fan et al., 2016; Liu et al., 2018).",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit33": {
        "SECTION": "| METHODS",
        "CITATION": "The dosing regimen was based on the pharmacokinetics data of XMU-MP-1 in a rodent model (Fan et al., 2016) and functional assays showing the effects of XMU-MP-1 injection (1 mg•kg -1) in reducing MOB1 phosphorylation in mice (Fan et al., 2016; Liu et al., 2018).",
        "REFERENCE": "(Fan et al., 2016;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit34": {
        "SECTION": "| METHODS",
        "CITATION": "The dosing regimen was based on the pharmacokinetics data of XMU-MP-1 in a rodent model (Fan et al., 2016) and functional assays showing the effects of XMU-MP-1 injection (1 mg•kg -1) in reducing MOB1 phosphorylation in mice (Fan et al., 2016; Liu et al., 2018).",
        "REFERENCE": "Liu et al., 2018)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit35": {
        "SECTION": "| METHODS",
        "CITATION": "Details of echocardiography analysis were described in previous publications (Mohamed et al., 2016; Zi et al., 2014).",
        "REFERENCE": "(Mohamed et al., 2016;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit36": {
        "SECTION": "| METHODS",
        "CITATION": "Details of echocardiography analysis were described in previous publications (Mohamed et al., 2016; Zi et al., 2014).",
        "REFERENCE": "Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit37": {
        "SECTION": "| METHODS",
        "CITATION": "Western blot analysis to detect protein expression was performed using standard methods as described previously (Mohamed et al., 2016).",
        "REFERENCE": "(Mohamed et al., 2016)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit38": {
        "SECTION": "| METHODS",
        "CITATION": "The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018).",
        "REFERENCE": "(Curtis et al., 2018)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit39": {
        "SECTION": "| METHODS",
        "CITATION": "Based on our previous study using Mst2 knockout mice in our laboratory (Zi et al., 2014), we predicted a 30% change in the HW/TL ratio between experimental groups with SD of 20% of the mean.",
        "REFERENCE": "(Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit40": {
        "SECTION": "| METHODS",
        "CITATION": "XMU-MP-1 (Fan et al., 2016) was obtained from MedChem Express.",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit41": {
        "SECTION": "| METHODS",
        "CITATION": "Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017; Alexander, Kelly et al., 2017).",
        "REFERENCE": "(Harding et al., 2018)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit42": {
        "SECTION": "| METHODS",
        "CITATION": "Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017; Alexander, Kelly et al., 2017).",
        "REFERENCE": "(Alexander, Fabbro et al., 2017;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit43": {
        "SECTION": "| METHODS",
        "CITATION": "Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017; Alexander, Kelly et al., 2017).",
        "REFERENCE": "Alexander, Kelly et al., 2017)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit44": {
        "SECTION": "| METHODS",
        "CITATION": "We and others have shown that both Mst1 and Mst2 are involved in regulating cardiomyocyte hypertrophy (Del Re et al., 2010; Zi et al., 2014).",
        "REFERENCE": "(Del Re et al., 2010;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit45": {
        "SECTION": "| METHODS",
        "CITATION": "We and others have shown that both Mst1 and Mst2 are involved in regulating cardiomyocyte hypertrophy (Del Re et al., 2010; Zi et al., 2014).",
        "REFERENCE": "Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit46": {
        "SECTION": "| METHODS",
        "CITATION": "Mst1 and Mst2 exert pro-apoptotic activity in a number of different cell types (Galan & Avruch, 2016).",
        "REFERENCE": "(Galan & Avruch, 2016)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit47": {
        "SECTION": "| METHODS",
        "CITATION": "Inhibition of the Hippo pathway and activation of YAP are known to induce cell proliferation (Heallen et al., 2013; Leach et al., 2017; Lin et al., 2014).",
        "REFERENCE": "(Heallen et al., 2013;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit48": {
        "SECTION": "| METHODS",
        "CITATION": "Inhibition of the Hippo pathway and activation of YAP are known to induce cell proliferation (Heallen et al., 2013; Leach et al., 2017; Lin et al., 2014).",
        "REFERENCE": "Leach et al., 2017;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit49": {
        "SECTION": "| METHODS",
        "CITATION": "Inhibition of the Hippo pathway and activation of YAP are known to induce cell proliferation (Heallen et al., 2013; Leach et al., 2017; Lin et al., 2014).",
        "REFERENCE": "Lin et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit50": {
        "SECTION": "| METHODS",
        "CITATION": "These data are in line with the previous reports using mice with genetic knockout of Mst1 and Mst2 (Del Re et al., 2010; Zi et al., 2014).",
        "REFERENCE": "(Del Re et al., 2010;",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit51": {
        "SECTION": "| METHODS",
        "CITATION": "These data are in line with the previous reports using mice with genetic knockout of Mst1 and Mst2 (Del Re et al., 2010; Zi et al., 2014).",
        "REFERENCE": "Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Methods"
        ]
    },
    "cit52": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Mst2 knockout mice displayed less hypertrophy, fibrosis, and apoptosis following TAC stimulation (Zi et al., 2014).",
        "REFERENCE": "(Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit53": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Likewise, inhibition of Mst1 by expressing a dominant negative mutant form of this kinase reduced apoptosis and protected against cardiac dysfunction following myocardial infarction (Odashima et al., 2007).",
        "REFERENCE": "(Odashima et al., 2007)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit54": {
        "SECTION": "| DISCUSSION",
        "CITATION": "In keeping with this finding, overexpression of Mst1 caused dilated cardiomyopathy due to excessive apoptosis (Yamamoto et al., 2003).",
        "REFERENCE": "(Yamamoto et al., 2003)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit55": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Regulation of the pro-apoptotic protein, Bcl-xL has been suggested as a possible mechanism of Mst1-dependent apoptosis in the cardiomyocytes (Del Re et al., 2014).",
        "REFERENCE": "(Del Re et al., 2014)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit56": {
        "SECTION": "| DISCUSSION",
        "CITATION": "In addition, activation of JNK and protein cleavage by caspase is also involved in Mst1-mediated apoptosis (Ura, Masuyama, Graves, & Gotoh, 2001).",
        "REFERENCE": "(Ura, Masuyama, Graves, & Gotoh, 2001)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit57": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Sav1 is an adaptor molecule that positively modulates Hippo signal activation (Misra & Irvine, 2018).",
        "REFERENCE": "(Misra & Irvine, 2018)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit58": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Heallen et al. showed that ablation of Sav1 produced beneficial effects in the heart in a model of myocardial infarction (Heallen et al., 2013).",
        "REFERENCE": "(Heallen et al., 2013)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit59": {
        "SECTION": "| DISCUSSION",
        "CITATION": "It was suggested that the increase in cardiomyocyte proliferation was the underlying mechanism for the reduction of infarct size and preservation of cardiac function in Sav1 knockout mice (Heallen et al., 2013; Leach et al., 2017).",
        "REFERENCE": "(Heallen et al., 2013;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit60": {
        "SECTION": "| DISCUSSION",
        "CITATION": "It was suggested that the increase in cardiomyocyte proliferation was the underlying mechanism for the reduction of infarct size and preservation of cardiac function in Sav1 knockout mice (Heallen et al., 2013; Leach et al., 2017).",
        "REFERENCE": "Leach et al., 2017)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit61": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Consistent with the observations in Mst1 and Mst2 mouse models, genetic inhibition of Lats2 using a dominant negative mutant attenuated apoptosis and improved the phenotype following myocardial infarction in mice (Matsui et al., 2008).",
        "REFERENCE": "(Matsui et al., 2008)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit62": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Hippo signalling deactivates YAP by phosphorylation and cytoplasmic retention (Misra & Irvine, 2018).",
        "REFERENCE": "(Misra & Irvine, 2018)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit63": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Expression of constitutively active YAP increased cardiomyocyte proliferation, reduced infarct size, and improved cardiac function in a model of myocardial infarction (Lin et al., 2014; Xin et al., 2013).",
        "REFERENCE": "(Lin et al., 2014;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit64": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Expression of constitutively active YAP increased cardiomyocyte proliferation, reduced infarct size, and improved cardiac function in a model of myocardial infarction (Lin et al., 2014; Xin et al., 2013).",
        "REFERENCE": "Xin et al., 2013)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit65": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Moreover, in response to myocardial infarction, YAP-deficient mice displayed more severe injury and reduction of cardiac function (Del Re et al., 2013; Xin et al., 2013).",
        "REFERENCE": "(Del Re et al., 2013;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit66": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Moreover, in response to myocardial infarction, YAP-deficient mice displayed more severe injury and reduction of cardiac function (Del Re et al., 2013; Xin et al., 2013).",
        "REFERENCE": "Xin et al., 2013)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit67": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Pharmacological modulation of the Hippo pathway is difficult to achieve because most of the upstream regulators of YAP do not have enzymic activity (Johnson & Halder, 2014).",
        "REFERENCE": "(Johnson & Halder, 2014)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit68": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Of several signalling branches that can modulate YAP, only the Mst1/2-Lats1/2 axis consists principally of kinases, making this pathway an attractive target for inhibitor development (Johnson & Halder, 2014).",
        "REFERENCE": "(Johnson & Halder, 2014)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit69": {
        "SECTION": "| DISCUSSION",
        "CITATION": "They reported a small molecule (9E1) that has a high potency in inhibiting Mst1 (IC 50 = 45 nM; Anand et al., 2009).",
        "REFERENCE": "Anand et al., 2009)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit70": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Using a cellular model, they found effectivity in inhibiting Mst1 by measuring Histone H2B phosphorylation (Anand et al., 2009).",
        "REFERENCE": "(Anand et al., 2009)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit71": {
        "SECTION": "| DISCUSSION",
        "CITATION": "In contrast to compound 9E1, this compound has been used in vivo to treat liver injury in mice, and the result was very promising (Fan et al., 2016).",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit72": {
        "SECTION": "| DISCUSSION",
        "CITATION": "This compound was able to induce cardiomyocyte proliferation both in vitro and in vivo, and treatment with TT-10, albeit at very high dose, improved the cardiac phenotype in a mouse model of myocardial infarction (Hara et al., 2018).",
        "REFERENCE": "(Hara et al., 2018)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit73": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Previous studies using XMU-MP-1 (Fan et al., 2016) and the YAP activator TT-10 (Hara et al., 2018) showed increases in proliferation of hepatocytes, small intestinal epithelial cells, and cardiomyocytes following in vivo treatment with the compounds.",
        "REFERENCE": "(Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit74": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Previous studies using XMU-MP-1 (Fan et al., 2016) and the YAP activator TT-10 (Hara et al., 2018) showed increases in proliferation of hepatocytes, small intestinal epithelial cells, and cardiomyocytes following in vivo treatment with the compounds.",
        "REFERENCE": "(Hara et al., 2018)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit75": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Inhibition of these kinases is beneficial to prevent pancreatic damage and development of diabetes as well as to induce liver regeneration (Ardestani et al., 2014; Fan et al., 2016).",
        "REFERENCE": "(Ardestani et al., 2014;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit76": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Inhibition of these kinases is beneficial to prevent pancreatic damage and development of diabetes as well as to induce liver regeneration (Ardestani et al., 2014; Fan et al., 2016).",
        "REFERENCE": "Fan et al., 2016)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit77": {
        "SECTION": "| DISCUSSION",
        "CITATION": "Mst1 inhibition also produces positive effects during adult somatic cell reprogramming to induced pluripotent stem cells (Robertson et al., 2017).",
        "REFERENCE": "(Robertson et al., 2017)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit78": {
        "SECTION": "| DISCUSSION",
        "CITATION": "However, total genetic ablation of Mst1 and Mst2 is also associated with the development of cancer in the liver and intestines (Song et al., 2010; Zhou et al., 2011).",
        "REFERENCE": "(Song et al., 2010;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit79": {
        "SECTION": "| DISCUSSION",
        "CITATION": "However, total genetic ablation of Mst1 and Mst2 is also associated with the development of cancer in the liver and intestines (Song et al., 2010; Zhou et al., 2011).",
        "REFERENCE": "Zhou et al., 2011)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit80": {
        "SECTION": "| DISCUSSION",
        "CITATION": "In addition, the fact that most of the components of this pathway are expressed and differentially regulated in diseased human hearts (Leach et al., 2017; Zi et al., 2014) make this pathway an interesting target for therapy.",
        "REFERENCE": "(Leach et al., 2017;",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    },
    "cit81": {
        "SECTION": "| DISCUSSION",
        "CITATION": "In addition, the fact that most of the components of this pathway are expressed and differentially regulated in diseased human hearts (Leach et al., 2017; Zi et al., 2014) make this pathway an interesting target for therapy.",
        "REFERENCE": "Zi et al., 2014)",
        "ALIGNED SECTION": [
            "Discussion"
        ]
    }
}